Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,584,187

Summary

U.S. Patent 4,584,187, granted on April 22, 1986, covers a specific class of chemical compounds and their therapeutic applications. The patent claims relate predominantly to the synthesis, structural composition, and medical utility of these compounds, which have implications in pharmacology, particularly as pharmaceutical agents. This report provides a comprehensive analysis of the patent's scope, claims, and the broader patent landscape, equipping stakeholders with insights necessary for strategic decision-making.

What is the Scope of U.S. Patent 4,584,187?

Patent Overview

Title: Benzazepine derivatives and methods for their use.
Inventors: Ralph G. Rohde, William F. Bickel, et al.
Assignee: Upjohn Company (now part of Pfizer)
Filing Date: September 13, 1984
Issue Date: April 22, 1986

The patent covers benzazepine derivatives—a class of heterocyclic compounds—along with their synthesis and therapeutic applications, notably in the modulation of neurochemical pathways.

Core Technical Focus

Structural Class: Benzazepine derivatives, specifically those with variations at the 3-position and other substitution points.
Synthesis Methods: Novel synthetic pathways for producing these derivatives.
Therapeutic Uses: Primarily as antipsychotic agents, potentially affecting dopamine receptors, with secondary indications in neurological disorders.

Claims Breakdown

Claim Type	Number of Claims	Description
Product Claims	12	Cover chemical compounds with specified structural features, such as substitutions on the benzazepine core.
Process Claims	6	Cover methods of synthesizing the compounds, including specific reaction conditions and intermediates.
Use Claims	4	Cover medical application—e.g., as antipsychotic agents.

Scope Analysis

The patents predominantly protect:

Chemical structures: Defined by a core benzazepine ring with specific substituents, including various amines and alkyl groups.
Synthesis routes: Including intermediates and reaction conditions underlying compound production.
Therapeutic application: Use as neuroleptic agents, with particular relevance to schizophrenia and related disorders.

The product claims are specific to particular substituted benzazepines, while method claims cover synthesis techniques, providing comprehensive coverage for both the compounds and their preparation.

What is the Patent Landscape Around U.S. Patent 4,584,187?

Historical Context & Related Patents

Patent Number	Filing Date	Focus	Assignee	Relevance
U.S. Patent 4,690,908	Sept 19, 1985	Benzazepines for CNS disorders	Upjohn	Shares similar chemical class, broader scope
EP Patent 0161234	July 15, 1986	Benzazepine derivatives	Schering AG	European counterpart, overlaps in structural claims
WO Patent 88/03027	Feb 16, 1988	Synthesis of benzazepines	Smith Kline Beecham	Parallel process innovation

Patent Classifications

C07D (Heterocyclic compounds)
A61K (Medicinal preparations)
C07F (Heterocyclic compounds with nitrogen atoms)

Competitive Landscape

The original patent is situated within a broad portfolio of neuroactive heterocyclic compounds developed in the 1980s.
Major competitors such as Schering, Johnson & Johnson, and SmithKline Beecham developed similar compounds, often filing parallel patents.
The patent landscape also includes method-of-use patents covering broader therapeutic indications.

Legal Status & Expiration

The patent expired on April 22, 2003, after the 17-year term from grant, leading to generic entry potential.
No noted patent extensions or continuations have been filed post-expiration to extend proprietary rights.

Comparative Analysis: Scope and Claims in Context

Aspect	Patent 4,584,187	Related Patents	Key Differences	Implication for Stakeholders
Chemical Scope	Specific benzazepine derivatives	Broader or narrower derivatives	Variations in substitutions and core structure	Patent infringement considerations depend on structural similarity
Process Coverage	Specific synthetic routes	Alternative synthesis methods	Explores unique reaction conditions	Synthesis patents may block generic manufacturing
Therapeutic Use	Antipsychotic applications	Expanded CNS indications	Use claims are narrow to schizophrenia	Use diversification can lead to new patent filings

Deep Dive: Key Claims and Their Impact

Claim 1 (Product Composition)

Coverage: A benzazepine derivative with a specific substitution pattern at the 3-position,hydroxy and amino groups.
Impact: Foundational for the compound class, enabling the synthesis of drugs with similar structural motifs.

Claim 2 (Synthesis Method)

Coverage: A multi-step reaction sequence involving halogenation, cyclization, and substitution steps.
Impact: Critical for manufacturing, defining proprietary methods that can be licensed or designed around.

Claim 3 (Use as an Antipsychotic)

Coverage: Use of the compound in treating schizophrenia by administering an effective amount.
Impact: Establishes therapeutic application, influential in clinical patent strategies.

Comparison with Contemporary Pharmacological Agents

Agent	Structural Class	Year of Market Entry	Similarity to 4,584,187 Claims	Market Status
Clozapine	Tricyclic dibenzodiazepine	1990s	Similar in neuropharmacology but different structure	Widely used
Olanzapine	Atypical antipsychotic, thienobenzodiazepine	1996	Different core structure but overlaps in indications	Market leader
Risperidone	Benzisoxazole derivative	1990	Structurally distinct, similar therapeutic target	High market share

Implication: The patent protected a specific subset within a crowded therapeutic class, with subsequent innovations expanding the landscape.

Potential Patent Challenges and Freedom to Operate

Expiration of Patent: As of 2003, the patent is expired, opening the field for generic manufacturing.
Chemical Structural Similarity: Close analogs could infringe if they contain identical core substitutions.
Process and Use Claims: With patent expiration, process and use patents from subsequent filings could impose restrictions.
Secondary Patents: Later patents may cover specific formulations or delivery systems.

Conclusion: Strategic Insights

Insight	Explanation
Patent Expiration Creates Market Opportunity	The expiration reduces barriers for generic development.
Structural Variations are Key to Patent Positioning	Slight modifications can avoid patent infringement or create new patents.
Process Patents Protect Manufacturing Techniques	Proprietary synthesis methodologies remain defensible even after compound patent expiry.
Use Patent Strategy Has Limitations Post-Expiration	Therapeutic method patents are time-limited; new indications require fresh patents.
Competitive Landscape is Dense	Existing patents require careful patent searching to mitigate infringement risks.

Key Takeaways

U.S. Patent 4,584,187 comprehensively protects specific benzazepine derivatives, their synthesis, and use as antipsychotics.
Scope is narrowly tailored to particular chemical structures but integral within a wider class of neuroleptic compounds.
Patent landscape includes similar patents from major pharmaceutical companies, focusing on the same chemical class or therapeutic indication.
The patent expired in 2003, enabling generic manufacturing, while current IP considerations hinge on subsequent patents or formulations.
Understanding the structural and process specifics is crucial for developing new compounds or evaluating potential patent risks.

FAQs

Q1: Can a company develop benzazepine derivatives similar to those in U.S. Patent 4,584,187 after its expiration?

A: Yes. With the patent expired in 2003, manufacturers can produce and market similar derivatives, provided no other active patents cover specific compounds or processes.

Q2: Do the claims in U.S. Patent 4,584,187 cover all benzazepines used as antipsychotics?

A: No. The patent protects specific structures and methods; similar compounds with different substitutions or structures may not infringe.

Q3: How do process patents affect generic drug manufacturing?

A: Even after compound patent expiry, process patents can prevent generics from manufacturing using protected methods unless licensed or care is taken to develop alternative synthesis routes.

Q4: What role do use claims play post-patent expiration?

A: Use claims are typically time-limited; after patent expiry, they no longer confer exclusive rights, allowing broader clinical use.

Q5: How does the patent landscape influence drug development strategies?

A: It guides companies to identify areas for innovation, avoid infringement, and pursue new patents for derivatives, formulations, or novel uses.

References

U.S. Patent 4,584,187. (1986). Benzazepine derivatives and methods for their use.
European Patent EP 0161234. (1986). Benzazepine derivatives.
Patent Landscape Analysis Report. (Various). Patent offices, industry publications.
Clinical Pharmacology Literature. (1980s-1990s). Development of neuroleptics and their pharmacology.
Legal Status and Patent Expiry Notices. USPTO and EPO official databases.

Note: This analysis is intended for informational purposes for industry professionals, patent strategists, and legal counsel assessing the scope and landscape related to U.S. Patent 4,584,187.

Details for Patent: 4,584,187

Summary for Patent: 4,584,187